Research programme: Bcl-2 inhibitors - Infinity/NovartisAlternative Names: Bcl-2 inhibitors - Infinity/Novartis
Latest Information Update: 30 Apr 2012
At a glance
- Originator Infinity Pharmaceuticals
- Developer Novartis
- Class Small molecules
- Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Cancer
Most Recent Events
- 30 Apr 2012 Early research is ongoing in USA
- 06 Mar 2006 Early research in Cancer in USA (unspecified route)